长期以来，国内儿童IFD治疗领域面临着巨大的临床挑战。一方面是由于儿童药物代谢动力学特征与成 人存在显著差异，导致现有药物在儿童体内的血药浓度波动大，难以达到理想的治疗效果；另一方面， 在侵袭性真菌病的临床治疗中，抗真菌药物的选择不仅需要考虑致病病原体和感染部位，还需结合患者 的整体临床背景进行个体化评估。传统抗真菌药物可能的脏器损害及复杂的药物相互作用，使得临床医 生在用药时不得不极其慎重。 康新博®儿科适应症的获批，为国内儿童IFD治疗提供了循证基础明确的规范化用药选择。辉瑞中国注 册事务部负责人王海辉表示："每一个儿童用药的审批，都是对药品有效性与安全性的双重考验。康新 博®儿科适应症的获批，建立在充分的临床证据和严格审评审批基础之上，是对儿童侵袭性真菌病治疗 领域长期存在的用药需求的积极回应，体现了各方为提升中国儿科患者治疗水平所秉持的信念与共同的 努力。" 来源：环球网 近日，辉瑞抗感染领域重磅创新药物康新博®（通用名：硫酸艾沙康唑胶囊，规格：40mg）获得中国 国家药品监督管理局（NMPA）批准，用于治疗体重≥16千克 (kg)的6至18岁以下儿童患者的侵袭性曲霉 病（IA）和侵袭性毛霉病（IM） ...

In this articlePFEAlbert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | ReutersA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Pfizer made one thing clear this week: It's officially back in the obesity race. The drugmaker is laser-focused on bringing to market treat ...

Analysts are on the fence about VFC stock. Of the 22 analysts that cover it, only three rate it a Buy (3.00 out of 5), with an $18.58 target price. However, the Barchart Technical Opinion is a Strong Buy, indicating a much more positive near-term outlook.The apparel and footwear manufacturer, whose three leading brands are The North Face, Vans, and Timberland, is in the midst of a turnaround that’s seen divestitures, job cuts, and other drastic measures to rightsize the business and prepare it for renewed g ...

Key Takeaways Pfizer plans to initiate or advance about 20 pivotal studies in 2026 across its obesity and oncology programs.PFE's PF'3944 showed robust weight loss in a phase IIb VESPER-3 obesity study.PFE oncology push includes PF-08634404 in phase III colorectal trials & upcoming data for sigvotatug vedotin.In 2025, Pfizer (PFE) upped its efforts to rebuild its pipeline through acquisitions. Pfizer invested around $9 billion in M&A deals, including the acquisition of Metsera and the licensing deal with 3S ...

Core Viewpoint - Pfizer Inc. has received Priority Review from the U.S. FDA for its supplemental Biologics License Application for HYMPAVZI® (marstacimab), aiming to expand its indication for treating hemophilia A or B patients aged 6 years and older with inhibitors, as well as pediatric patients aged 6 to 11 with hemophilia A or B without inhibitors [1] Group 1 - The FDA has accepted Pfizer's supplemental Biologics License Application for HYMPAVZI® [1] - The application seeks to expand the treatment indication to include hemophilia A or B patients aged 6 years and older with inhibitors [1] - The application also targets pediatric patients aged 6 to 11 with hemophilia A or B without inhibitors [1]

2026.02. 06 本文字数：1690，阅读时长大约3分钟 作者 | 第一财经 孙卓 当地时间周四（2月5日），特朗普发表全国电视讲话称将推出名为"特朗普药房"（TrumpRx）的新网站，旨在让美国民众以大幅折扣价格直接向药品制 造商购买处方药。 白宫发表声明称，TrumpRx的核心在于绕过中间环节和传统保险体系，以政府协议折扣价直接向制药商购买特定药品，从而为民众降低处方药价格。 特朗普表示，新的政府协议将改变这种局面。 "根据我的政府与制药公司谈判达成的协议，美国将支付所有国家中最低的价格。我们将获得世界上任何地方的最低价格。这就是你们将要支付的价 格。"特朗普说，"这些药价对美国来说将大幅下降——降幅高达300%、400%、500%，甚至600%。"特朗普说。"在某些情况下，降幅甚至更大。" 特朗普当天列举了一系列他声称价格将会降低的药物，包括辅助生育药物、胰岛素和减肥药等40多种药物。 白宫的声明称，这些价格反映了其与十多家制药公司-包括安进、礼来、吉利德和辉瑞等公司根据"最惠国"药品定价协议谈判达成的折扣。 和关税有关？ 特朗普当天在白宫的活动中说，"美国人长期以来一直在为药品支付全球最高的价格 ...

白宫发表声明称，TrumpRx的核心在于绕过中间环节和传统保险体系，以政府协议折扣价直接向制药商 购买特定药品。 当地时间周四（2月5日），特朗普发表全国电视讲话称将推出名为"特朗普药房"（TrumpRx）的新网 站，旨在让美国民众以大幅折扣价格直接向药品制造商购买处方药。 白宫发表声明称，TrumpRx的核心在于绕过中间环节和传统保险体系，以政府协议折扣价直接向制药商 购买特定药品，从而为民众降低处方药价格。 和关税有关？ 白宫的声明称，这些价格反映了其与十多家制药公司-包括安进、礼来、吉利德和辉瑞等公司根据"最惠 国"药品定价协议谈判达成的折扣。 据报道，在同每一家制药公司达成的协议中，特朗普政府都同意放弃对制药行业征收关税的计划，以换 取制药公司以折扣价向医疗补助计划（Medicaid）和通过TrumpRx直接向消费者销售药品。 在去年3月，特朗普签署一项行政命令称，制药公司已同意"以不高于其他可比国家的价格销售处方 药"，特朗普称，这可以被称为是一项药品定价的"最惠国待遇"政策。 特朗普当天在白宫的活动中说，"美国人长期以来一直在为药品支付全球最高的价格，而其他国家却只 需支付同样药品价格的零头。" ...

Market Analysis by covering: Pfizer Inc. Read 's Market Analysis on Investing.com ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for their prescription medicines. ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.Eli Lilly's (LLY +10.33%) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes drug Mounjaro, which is also marketed for treating obesity outside of the U.S., Canada, and Japan, raked in nearly $23 billion last year. Meanwhile, Novo Nordisk's (NVO 6.22%) obesity franchise made the Denmark-based drugmaker 82.3 billion Danish krone (roughly $13 billion). What was Pfizer's (PFE +4.08%) revenue in the obes ...